Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years Read more about Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years
ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis Read more about ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis
FDA Approves Enbrel Manufacturing Facility; Supply For Patients Dramatically Increases Read more about FDA Approves Enbrel Manufacturing Facility; Supply For Patients Dramatically Increases
Nominations Open for the Amgen Award for Science Teaching Excellence Read more about Nominations Open for the Amgen Award for Science Teaching Excellence
AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors Read more about AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors
Amgen's Third Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 22 Percent to $1.04 Read more about Amgen's Third Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 22 Percent to $1.04
U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit Read more about U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit
Amgen Foundation Launches $25 Million Undergraduate Research Program Read more about Amgen Foundation Launches $25 Million Undergraduate Research Program
Amgen Receives Complete Response Letter for Extended Dosing of Aranesp(R) for Patients with Chronic Kidney Disease and Anemia Read more about Amgen Receives Complete Response Letter for Extended Dosing of Aranesp(R) for Patients with Chronic Kidney Disease and Anemia
